Recessive mutations in MEGF10 (SR-F3) in humans result in early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD), but the mechanism underlying the pathogenesis of the disease is unknown62. Here, MEGF10 is linked to MEGF10-related myopathy.